vs

Side-by-side financial comparison of Stryker Corporation (SYK) and Visa Inc. (V). Click either name above to swap in a different company.

Visa Inc. is the larger business by last-quarter revenue ($11.2B vs $7.2B, roughly 1.6× Stryker Corporation). Visa Inc. runs the higher net margin — 53.4% vs 11.8%, a 41.6% gap on every dollar of revenue. On growth, Visa Inc. posted the faster year-over-year revenue change (17.0% vs 11.4%). Over the past eight quarters, Stryker Corporation's revenue compounded faster (16.9% CAGR vs 12.3%).

The Stryker is a family of eight-wheeled armored fighting vehicles derived from the Canadian LAV III, which in turn derived from the Swiss Mowag Piranha. Stryker vehicles are produced by General Dynamics Land Systems-Canada (GDLS-C) for the United States Army in a plant in London, Ontario. It has four-wheel drive (8×4) and can be switched to all-wheel drive (8×8).

Visa Inc. is an American multinational payment card services corporation headquartered in San Francisco, California. It facilitates electronic funds transfers throughout the world, most commonly through Visa-branded credit cards, debit cards and prepaid cards.

SYK vs V — Head-to-Head

Bigger by revenue
V
V
1.6× larger
V
$11.2B
$7.2B
SYK
Growing faster (revenue YoY)
V
V
+5.6% gap
V
17.0%
11.4%
SYK
Higher net margin
V
V
41.6% more per $
V
53.4%
11.8%
SYK
Faster 2-yr revenue CAGR
SYK
SYK
Annualised
SYK
16.9%
12.3%
V

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
SYK
SYK
V
V
Revenue
$7.2B
$11.2B
Net Profit
$849.0M
$6.0B
Gross Margin
64.5%
Operating Margin
25.2%
64.4%
Net Margin
11.8%
53.4%
Revenue YoY
11.4%
17.0%
Net Profit YoY
55.5%
32.0%
EPS (diluted)
$2.20

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SYK
SYK
V
V
Q2 26
$11.2B
Q4 25
$7.2B
$10.9B
Q3 25
$6.1B
$10.7B
Q2 25
$6.0B
$10.2B
Q1 25
$5.9B
$9.6B
Q4 24
$6.4B
$9.5B
Q3 24
$5.5B
$9.6B
Q2 24
$5.4B
$8.9B
Net Profit
SYK
SYK
V
V
Q2 26
$6.0B
Q4 25
$849.0M
$5.9B
Q3 25
$859.0M
$5.1B
Q2 25
$884.0M
$5.3B
Q1 25
$654.0M
$4.6B
Q4 24
$546.0M
$5.1B
Q3 24
$834.0M
$5.3B
Q2 24
$825.0M
$4.9B
Gross Margin
SYK
SYK
V
V
Q2 26
Q4 25
64.5%
Q3 25
63.6%
Q2 25
63.8%
Q1 25
63.8%
Q4 24
64.9%
Q3 24
64.0%
Q2 24
63.0%
Operating Margin
SYK
SYK
V
V
Q2 26
64.4%
Q4 25
25.2%
61.8%
Q3 25
18.7%
57.3%
Q2 25
18.5%
60.7%
Q1 25
14.3%
56.6%
Q4 24
9.0%
65.6%
Q3 24
19.7%
66.0%
Q2 24
19.4%
66.7%
Net Margin
SYK
SYK
V
V
Q2 26
53.4%
Q4 25
11.8%
53.7%
Q3 25
14.2%
47.5%
Q2 25
14.7%
51.8%
Q1 25
11.1%
47.7%
Q4 24
8.5%
53.8%
Q3 24
15.2%
55.3%
Q2 24
15.2%
54.7%
EPS (diluted)
SYK
SYK
V
V
Q2 26
Q4 25
$2.20
Q3 25
$2.22
Q2 25
$2.29
Q1 25
$1.69
Q4 24
$1.41
Q3 24
$2.16
Q2 24
$2.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SYK
SYK
V
V
Cash + ST InvestmentsLiquidity on hand
$4.0B
$12.4B
Total DebtLower is stronger
$22.4B
Stockholders' EquityBook value
$22.4B
$35.7B
Total Assets
$47.8B
$95.0B
Debt / EquityLower = less leverage
0.63×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SYK
SYK
V
V
Q2 26
$12.4B
Q4 25
$4.0B
$14.8B
Q3 25
$3.3B
$17.2B
Q2 25
$2.4B
$17.1B
Q1 25
$2.3B
$11.7B
Q4 24
$3.7B
$12.4B
Q3 24
$3.9B
$12.0B
Q2 24
$1.9B
$12.9B
Total Debt
SYK
SYK
V
V
Q2 26
$22.4B
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Stockholders' Equity
SYK
SYK
V
V
Q2 26
$35.7B
Q4 25
$22.4B
$38.8B
Q3 25
$21.8B
$37.9B
Q2 25
$21.2B
$38.7B
Q1 25
$20.9B
$38.0B
Q4 24
$20.6B
$38.3B
Q3 24
$20.1B
$39.1B
Q2 24
$19.8B
$39.7B
Total Assets
SYK
SYK
V
V
Q2 26
$95.0B
Q4 25
$47.8B
$96.8B
Q3 25
$47.1B
$99.6B
Q2 25
$46.3B
$100.0B
Q1 25
$46.0B
$92.9B
Q4 24
$43.0B
$91.9B
Q3 24
$43.8B
$94.5B
Q2 24
$39.1B
$91.0B
Debt / Equity
SYK
SYK
V
V
Q2 26
0.63×
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SYK
SYK
V
V
Operating Cash FlowLast quarter
$2.1B
Free Cash FlowOCF − Capex
$1.9B
FCF MarginFCF / Revenue
26.1%
Capex IntensityCapex / Revenue
3.7%
Cash ConversionOCF / Net Profit
2.52×
TTM Free Cash FlowTrailing 4 quarters
$4.3B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SYK
SYK
V
V
Q2 26
Q4 25
$2.1B
$6.8B
Q3 25
$1.5B
$6.2B
Q2 25
$1.1B
$6.7B
Q1 25
$250.0M
$4.7B
Q4 24
$1.9B
$5.4B
Q3 24
$1.5B
$6.7B
Q2 24
$633.0M
$5.1B
Free Cash Flow
SYK
SYK
V
V
Q2 26
Q4 25
$1.9B
$6.4B
Q3 25
$1.4B
$5.8B
Q2 25
$928.0M
$6.3B
Q1 25
$127.0M
$4.4B
Q4 24
$1.7B
$5.1B
Q3 24
$1.3B
$6.4B
Q2 24
$481.0M
$4.7B
FCF Margin
SYK
SYK
V
V
Q2 26
Q4 25
26.1%
58.7%
Q3 25
22.3%
54.5%
Q2 25
15.4%
62.0%
Q1 25
2.2%
45.5%
Q4 24
25.9%
53.1%
Q3 24
23.7%
66.1%
Q2 24
8.9%
53.2%
Capex Intensity
SYK
SYK
V
V
Q2 26
Q4 25
3.7%
3.5%
Q3 25
3.1%
3.6%
Q2 25
3.0%
4.1%
Q1 25
2.1%
3.4%
Q4 24
4.1%
3.6%
Q3 24
3.1%
3.2%
Q2 24
2.8%
4.5%
Cash Conversion
SYK
SYK
V
V
Q2 26
Q4 25
2.52×
1.16×
Q3 25
1.79×
1.23×
Q2 25
1.26×
1.28×
Q1 25
0.38×
1.03×
Q4 24
3.54×
1.05×
Q3 24
1.77×
1.25×
Q2 24
0.77×
1.05×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

SYK
SYK

Medical$1.3B18%
Endoscopy$1.1B16%
Traumaand Extremities$1.1B15%
Instruments$925.0M13%
Knees$749.0M10%
Neuro Cranial$669.0M9%
Neurovascular$539.0M8%
Hips$499.0M7%
Other Orthopaedics$267.0M4%
Spine$8.0M0%

V
V

Data processing revenue$5.5B49%
International transaction revenue$3.6B32%
Other revenue$1.3B12%
Other$736.0M7%

Related Comparisons